betamethasone benzoate 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
351 22298-29-9

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • betamethasone benzoate
  • betamethasone 17-benzoate
  • Molecular weight: 496.58
  • Formula: C29H33FO6
  • CLOGP: 3.97
  • LIPINSKI: 0
  • HAC: 6
  • HDO: 2
  • TPSA: 100.90
  • ALOGS: -5.12
  • ROTB: 5
  • Status: OFM
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

None

ADMET properties:

PropertyValueReference
S (Water solubility) 0.06 mg/mL Bocci G, Oprea TI, Benet LZ

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
azlogd74 LogD at pH 7.4 3.382 Moderate 0.70
caco2-efflux Caco-2 efflux ratio (BA/AB) 0.789 Moderate 0.70
caco2-intrinsic-papp Caco-2 intrinsic apparent permeability 76.560 10^-6 cm/s Moderate 0.70
dh-clint Dog hepatocyte intrinsic clearance 18.707 uL/min/10^6 cells Moderate 0.70
dppb Dog plasma protein binding (% unbound) 3.080 % Moderate 0.70
fcs-ppb Fetal calf serum protein binding (% unbound) 6.640 % Moderate 0.70
herg hERG pIC50 4.575 pIC50 Moderate 0.70
hh-clint Human hepatocyte intrinsic clearance 41.879 uL/min/10^6 cells Moderate 0.70
hlm-clint Human liver microsomal intrinsic clearance 118.304 uL/min/mg protein Moderate 0.70
hppb Human plasma protein binding (% unbound) 3.260 % Moderate 0.70
kinase-safety-class ACVR2B,AXL,BRAF,CAMK2D,CDK5,EIF2AK3,ERBB2,GRK2,ITK,MAPK10,PDK1,PDK2,PDK4,PIK3CB,PRKDC 15
kinase-selectivity-class AXL,GRK2,MAP2K6 3
mdck-mdr1-bcrp-efflux MDCK-MDR1-BCRP efflux ratio 9.268 Moderate 0.69
mdck-mdr1-efflux MDCK-MDR1 efflux ratio 2.698 Moderate 0.70
mh-clint Mouse hepatocyte intrinsic clearance 70.958 Moderate 0.70
mppb Mouse plasma protein binding (% unbound) 3.700 Moderate 0.70
nih-mdck-mdr1-efflux NIH MDCK-MDR1 efflux ratio 12.618 Moderate 0.70
pfas-class PFAS structural alert (1 = True, 0 = False) 0
pld-class Phospholipidosis risk class (1 = positive, 0 = negative) 0 Moderate 0.69
pppb Pig plasma protein binding (% unbound) 7.840 % Moderate 0.70
rat-kpuu-brain Rat brain Kpuu 0.043 % Moderate 0.69
rh-clint Rat hepatocyte intrinsic clearance 147.571 uL/min/10^6 cells Moderate 0.70
rh-fuinc Rat hepatocyte fraction unbound in incubation 36.100 % Moderate 0.70
rppb Rat plasma protein binding (% unbound) 3.350 % Moderate 0.70
solubility-dd Solubility at pH 7.4 in DMSO 29.923 uM Moderate 0.70

Approvals:

DateAgencyCompanyOrphan
None FDA PARKE DAVIS

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

None

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
FDA MoA N0000175450 Corticosteroid Hormone Receptor Agonists
FDA EPC N0000175576 Corticosteroid
CHEBI has role CHEBI:35472 anti-inflammatory drug
CHEBI has role CHEBI:35480 analgesic
CHEBI has role CHEBI:35610 antineoplastic agent
CHEBI has role CHEBI:35705 immunosuppressive agent
CHEBI has role CHEBI:35845 gout suppressant
CHEBI has role CHEBI:39456 antiglaucoma drug
CHEBI has role CHEBI:49201 anti-ulcer drug
CHEBI has role CHEBI:50177 dermatologic drug
CHEBI has role CHEBI:50748 antipsoriatic
CHEBI has role CHEBI:51177 antitussive
CHEBI has role CHEBI:65023 anti-asthmatic agent
CHEBI has role CHEBI:66981 ophthalmology drug
CHEBI has role CHEBI:77715 nasal decongestant
MeSH PA D000893 Anti-Inflammatory Agents
MeSH PA D005938 Glucocorticoids
MeSH PA D006728 Hormones
MeSH PA D018927 Anti-Asthmatic Agents
MeSH PA D019141 Respiratory System Agents

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Atopic dermatitis indication 24079001 DOID:3310
Contact dermatitis indication 40275004 DOID:2773
Seborrheic dermatitis indication 50563003 DOID:8741
Lichen simplex chronicus indication 53891004
Granuloma annulare indication 65508009 DOID:3777
Pruritus ani indication 90446007
Discoid lupus erythematosus indication 200938002
Plaque psoriasis indication 200965009
Scalp psoriasis indication 238608008
Pruritus of genital organs indication 267802000
Eruption of skin indication 271807003 DOID:0050486
Primary cutaneous T-cell lymphoma indication 400122007
Telangiectasia disorder contraindication 247479008
Adrenal cortical hypofunction contraindication 386584007 DOID:10493
Atrophoderma contraindication 399979006
Peripheral vascular disease contraindication 400047006




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 11.29 acidic
pKa2 11.94 acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Glucocorticoid receptor Nuclear hormone receptor AGONIST CHEMBL CHEMBL

External reference:

IDSource
4018641 VUID
N0000146954 NUI
D02286 KEGG_DRUG
1514 RXNORM
C0005311 UMLSCUI
CHEBI:135798 CHEBI
CHEMBL1200376 ChEMBL_ID
C015706 MESH_SUPPLEMENTAL_RECORD_UI
877K0XW47A UNII
5282492 PUBCHEM_CID
DB00443 DRUGBANK_ID
10006 MMSL
4270 MMSL
4272 MMSL
d00628 MMSL
C0005308 UMLSCUI
9782 PUBCHEM_CID
1045 INN_ID
4018641 VANDF
4018644 VANDF
D001623 MESH_DESCRIPTOR_UI
002168 NDDF
002170 NDDF
116571008 SNOMEDCT_US
17908000 SNOMEDCT_US
29896003 SNOMEDCT_US
CHEBI:3077 CHEBI
877K0XW47A INXIGHT DRUGS

Pharmaceutical products:

None